Bey Douglas LLC Has $4.92 Million Position in Eli Lilly and Company $LLY

Bey Douglas LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 22.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,317 shares of the company's stock after purchasing an additional 1,157 shares during the quarter. Eli Lilly and Company comprises approximately 2.9% of Bey Douglas LLC's investment portfolio, making the stock its 16th largest holding. Bey Douglas LLC's holdings in Eli Lilly and Company were worth $4,924,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. WestEnd Advisors LLC boosted its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $27,000. Citizens National Bank Trust Department boosted its position in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after buying an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company during the 1st quarter worth $40,000. Finally, TD Capital Management LLC boosted its holdings in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after acquiring an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Morgan Stanley cut their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a report on Friday, October 3rd. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 20th. HSBC boosted their target price on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Guggenheim boosted their target price on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Deutsche Bank Aktiengesellschaft cut their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $948.56.

Insider Activity

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $833.08 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The business's 50 day simple moving average is $742.42 and its 200 day simple moving average is $765.94. The company has a market cap of $788.47 billion, a price-to-earnings ratio of 54.45, a PEG ratio of 1.16 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the business earned $3.92 earnings per share. Eli Lilly and Company's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.